Glaxosmithkline Stock News

GlaxoSmithKline plc (GSK) announced on Wednesday that its turnover rose 9% year on year to reach £9.5 billion in the fourth quarter of fiscal 2021. More to come...

Stocks, especially the once high flying technology stocks, had a lousy start to the new year. QQQ lost 9% of its value in January.

In the current session, GlaxoSmithKline Inc. (NYSE: GSK ) is trading at $45.05, after a 0.55% spike. Over the past month, the stock increased by 0.01% , and in the past year, by 26.00% . With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued. Also check out this: Executives Buy Around $62M Of 3 Stocks Assuming that all other factors are held constant, this could present itself as an opportunity Full story available on Benzinga.com

Key Events This Week: All Eyes On The CPI After what DB''s Jim Reid describes as "a week for the ages" this week should be calmer until of course US CPI comes along on Thursday. As the Deutsche strategist notes, in his look back at a hell of a week, what made last week so fascinating was the rare interplay between macro and micro. Not only did the rates world shake and reverberate (2yr bunds +35.9bps and the worse week since 2008), but on successive days we saw the biggest market cap fall in history for any company (Meta), followed by the biggest rise ever (Amazon). We have 83 S&P 500 companies reporting this week but no Goliath sized ones, so it''ll be a more normal week for earnings. The macro and micro last week was enough to push the Russian/Ukraine tensions into the background but they are clearly still there so we have to watch out for that as well. Over the weekend ECB governor Knott (a hawk) became the first ECB official to confirm what we reported last week, when he endorsed a 2022 hike by suggesting that he expects a hike around Q4 and another in Spring 2023, and that they are most likely to be in 25bps increments.

Futures Tread Water Amid Peripheral Bond Rout As Key CPI Print Looms U.S. index futures swung around in a volatile, illiquid overnight session, and at last check were flat despite traders'' concerns about growing fireworks in the European bond market where Italian and Greek bond plunged amid fears of ECB rate hikes as soon as October, while waiting for Thursday''s key CPI data and further corporate earnings. S&P 500 futures were up 2 points or 0.05%, Nasdaq futures were up 26 points or 0.18% and Dow futures were up fractionally as markets now expect more than five quarter-point Federal Reserve interest-rate hikes in 2022 to keep inflation on check following a strong U.S. jobs report. Treasury yields and the dollar were stable, while the euro snapped a six-day strengthening run. WTI crude fell after last week''s rally. Chinese shares climbed on their return from a weeklong holiday. Bitcoin extended its recovery surge. In the premarket, Peloton was in focus, soaring 27% on reports it''s evaluating interest from potential suitors including Amazon and Nike.

Top Unilever Plc (UL) shareholders are calling for the consumer goods company to make some major changes especially after its recent failed $68B bid for GlaxoSmithKline''s

Taibbi: The British Medical Journal Story That Exposed Politicized "Fact-Checking" Authored by Matt Taibbi via TK News , In February of 2010, the New York Times released a front-page story entitled, Research Ties Diabetes Drug to Heart Woes . The lede read: Hundreds of people taking Avandia, a controversial diabetes medicine, needlessly suffer heart attacks and heart failure each month, according to confidential government reports that recommend the drug be removed from the market. The Times piece quoted an internal F.D.A. report that said the GlaxoSmithKline diabetes drug Avandia, also known as Rosiglitazone, was linked to 304 deaths in 2009, adding the conclusion of the two doctors who authored the report: Rosiglitazone should be removed from the market. The story was released in advance of a Senate Finance Committee study that produced a series of damning internal documents, including one in which an FDA safety officer expressed concern that Avandia presented such serious cardiovascular risks that the safety of the study itself cannot be assured, and is not acceptable. One of the chief investigators on that study was Paul Thacker, at the time a committee aide under Iowa Republican Chuck Grassley.

GlaxoSmithKline (GSK) announced that ViiV Healthcare, majority-owned by the U.K

PALM BEACH, Fla. , Jan. 27, 2022 /PRNewswire/ -- FinancialNewsMedia.com News Commentary - According to International Agency for Research on Cancer (IARC) published by the World Health Organization (WHO) in 2018, breast cancer ranks as the fifth leading cause of deaths in women; accounting for 627,000 deaths every year. Moreover, as per estimates of the American Cancer Society, in U.S., 266,120 new cases were expected to be diagnosed in women by 2018. Furthermore, aging is considered as one of the greatest risk factors. According to Cancer Treatment Centers of America, women above 60 years of age are more likely to be diagnosed and only about 10% to 15% of cases occur in women younger than 45 years of age. High prevalence of the disease coupled with patent expiry are some of the major factors influencing investment in research and development of new products. The R&D spending from companies like Johnson & Johnson Services, Inc.; Merck & Co., Inc.; Celgene Corporation; Pfizer, Inc.; GlaxoSmithKline plc; Sanofi; and AbbVie, Inc. has increased exponentially.

GlaxoSmithKline (GSK) announced that the FDA approved 40 mg prefilled syringe of Nucala (mepolizumab) for children aged 6 11 years with severe eosinophilic asthma ((SEA)).Nucala

Activist hedge fund Trian Partners is said to take a stake in Unilever (UL) as shareholder pressure mounts after a failed attempt to acquire GlaxoSmithKline''s (GSK) consumer

GlaxoSmithKline <> and Vir Biotechnology <> are planning to add a second manufacturing facility in the U.S

After reaching a 52-week low on its failed bid to acquire the consumer unit of GlaxoSmithKline (GSK), Unilever (UL) ADRs rebounded Wednesday as the company ruled out raising the bid

Unilever, the maker of Vaseline skin care products and Dove soap, says it wont increase a 50 billion-pound ($68.2 billion) offer for GlaxoSmithKlines consumer healthcare unit that was rejected last week